跳至主要内容
临床试验/2022-500775-31-00
2022-500775-31-00招募中1 期

A study to investigate pharmacokinetics and safety of rupatadine (10 mg) and its active metabolites in participants with renal impairment compared to matched control participants with normal renal function.

Noucor Health S.A.7 个研究点 分布在 2 个国家目标入组 48 人开始时间: 2022年8月1日最近更新:
适应症

试验速览

阶段
1 期
状态
招募中
入组人数
48
试验地点
7

研究概览

简要总结

暂无简介。

入排标准

年龄范围
18 years 至 65+ years(65+ Years, 18-64 Years)
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究者

申办方类型
Pharmaceutical company
责任方
Principal Investigator
主要研究者

Daniel Peris

Scientific

Noucor Health S.A.

研究点 (7)

Loading locations...

相似试验

进行中(未招募)
不适用
Study to evaluate the safety and pharmacokinetics of ciprofloxacin following inhalation of ciprofloxacin dry powder for inhalation administered to pediatric patients with cystic fibrosis aged 12-17 yearslong term treatment of chronic lung infections caused by Pseudomonas aeruginosa in patients with cystic fibrosisMedDRA version: 8.1Level: LLTClassification code 10011763Term: Cystic fibrosis lung
EUCTR2007-002912-24-DEBayer HealthCare AG16
已完成
不适用
A study evaluating the pharmacokinetics, safety and tolerability of OP2113 administered intravenously in healthy volunteers and a marketed formulation administered orally
NL-OMON48072OP2 Drugs12
已完成
不适用
The aim of this study is to compare and evaluate the pharmacokinetic properties and safety of oral administration of test drugEndocrine, nutritional and metabolic diseases
KCT0004026Kyung Dong Pharmaceutical80
已完成
不适用
A study to evaluate the pharmacokinetics, safety and tolerability after inhalation of MMI-0100 in healthy subjects; MMI-0100 is an investigational drug developed for the treatment of fibrotic indications.Idiopathic pulmonary fibrosisidiopathische fibrosepulmonary diseases.
NL-OMON40896Moerae Matrix, Inc48
招募中
1 期
A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of AZD8630, Administered Once Daily via Inhalation, for 2 Weeks, in Adults with Asthma on Medium-to-high Dose Inhaled Corticosteroids and Long-acting Beta-agonistsAsthma
2024-514213-35-00AstraZeneca AB24